Dr Reddy's & Bayer Partner for Heart Failure Drug in India
By Rediff Money Desk, NEWDELHI Apr 05, 2024 20:00
Dr Reddy's Laboratories and Bayer collaborate to market Vericiguat, a drug for chronic heart failure, under the brand name Gantra in India, expanding access to patients.
![Dr Reddy's & Bayer Partner for Heart Failure Drug in India](https://im.rediff.com/money/2013/dec/24drug-pharma2.jpg)
New Delhi, Apr 5 (PTI) Dr Reddy's Laboratories on Friday said it has inked a pact with Bayer to market a second brand of Vericiguat, a drug indicated for chronic heart failure, in India.
In September 2022, Bayer launched the patented drug, Vericiguat, under the brand name Verquvo in India.
Under this pact, Dr Reddy's will market the drug under a second brand name Gantra in India, expanding the reach of Vericiguat to meet the needs of patients with chronic heart failure, the companies said in a joint statement.
Bayer has granted non-exclusive rights to Dr Reddy's for the product under the brand name Gantra, it added.
Heart failure is a major public health issue affecting more than 8-10 million people in India.
"The introduction of a second brand of Vericiguat in India, through our partnership with Dr Reddy's is a reaffirmation of our commitment to making innovative healthcare solutions accessible to as many patients as possible," Bayer Zydus Pharma Managing Director Shweta Rai said.
Dr Reddy's CEO of Branded Markets (India and Emerging Markets) MV Ramana said the partnership with Bayer is part of the company's continuous efforts to make innovative medicines available to patients in India through strategic collaborations.
"We will use our strengths in marketing and distribution to widen access to this novel treatment in metros and beyond into tier-I and tier-II towns in India," he added.
In September 2022, Bayer launched the patented drug, Vericiguat, under the brand name Verquvo in India.
Under this pact, Dr Reddy's will market the drug under a second brand name Gantra in India, expanding the reach of Vericiguat to meet the needs of patients with chronic heart failure, the companies said in a joint statement.
Bayer has granted non-exclusive rights to Dr Reddy's for the product under the brand name Gantra, it added.
Heart failure is a major public health issue affecting more than 8-10 million people in India.
"The introduction of a second brand of Vericiguat in India, through our partnership with Dr Reddy's is a reaffirmation of our commitment to making innovative healthcare solutions accessible to as many patients as possible," Bayer Zydus Pharma Managing Director Shweta Rai said.
Dr Reddy's CEO of Branded Markets (India and Emerging Markets) MV Ramana said the partnership with Bayer is part of the company's continuous efforts to make innovative medicines available to patients in India through strategic collaborations.
"We will use our strengths in marketing and distribution to widen access to this novel treatment in metros and beyond into tier-I and tier-II towns in India," he added.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 17.90 ( -3.35)
- 166585989
- Alstone Textiles
- 0.75 (+ 8.70)
- 47681821
- GTL Infrastructure
- 3.27 (+ 4.81)
- 44040612
- Visagar Financial
- 0.91 (+ 12.35)
- 29755394
- YES Bank Ltd.
- 23.70 (+ 0.77)
- 22163699
MORE NEWS
![Indian Economy...](https://im.rediff.com/80-80/money/2020/nov/22economy.jpg)
Indian Economy Growth: Exports, Manufacturing &...
Mumbai, June 30 (PTI) Healthy increase in the country's exports, improvement in the...
![India Launches...](https://im.rediff.com/80-80/news/2020/jul/imports-o.jpg)
India Launches Anti-Dumping Probe on Glass...
New Delhi, June 30 (PTI) India has initiated an anti-dumping probe into the import of...
![IBBI Launches...](https://im.rediff.com/80-80/money/2020/dec/16insolvency.jpg)
IBBI Launches Electronic Forms for Liquidation...
New Delhi, Jun 30 (PTI) To ease the compliance burden for insolvency professionals, and...